Call for Investment: Pioneering a Safer, Smarter Future in Breast Cancer Treatment

The International Center for Precision Medicine (P7 Medicine), is proud to announce a unique investment opportunity in the development of P7-ONCOVAX-B™, a next-generation targeted vaccine designed to revolutionize breast cancer therapy.

Why Breast Cancer: Breast cancer remains one of the most pressing global health challenges, claiming over 680,000 lives annually. Despite advances in surgery, chemotherapy, and hormone therapy, many patients still face relapse, resistance, and debilitating side effects. There is an urgent need for safer, more precise, and long-lasting solutions.

What Makes P7-ONCOVAX-B™ Different? P7-ONCOVAX-B™ is a synthetic vaccine that activates the immune system to selectively target cancer cells—without harming healthy tissue. This signal is only recognized by the immune system when presented by cancer cells, triggering a powerful and focused immune response.

Key Advantages:

• Precision Targeting: Attacks cancer cells while sparing healthy ones
• Immune Memory Activation: Offers long-term protection against recurrence
• Safety First: Avoids the toxicity of conventional treatments
• Versatile Platform: Potential to expand to other cancer types

Investment Opportunity We are seeking €2 million in strategic funding to complete preclinical studies and prepare for Phase 1 clinical trials within the next 18 months. This funding will accelerate:

• Final formulation and safety validation
• Regulatory preparation and trial design
• Expansion of manufacturing capabilities
• Strategic partnerships with clinical centers

Why Invest Now?

• Backed by a proven team of international scientists and clinicians
• Positioned at the intersection of immunotherapy and precision medicine
• Strong potential for licensing, co-development, and global market entry
• Social impact: contributing to a safer future for millions of women

Join Us Be part of a transformative journey in cancer care. For investment inquiries and partnership discussions, please contact:

Email: Khodayari@icpm.center

Phone: +49-179-2051555